Vesiculab’s Post

Did you know that fewer than 10% of new cancer drugs make it from the lab to market? The key to overcoming this challenge lies in using the right models for drug development. At MIMETAS, we're redefining cancer drug discovery with our advanced 3D cancer models that accurately replicate human tumor environments. By providing predictive insights, we help bridge the critical gap between preclinical research and clinical success. Discover how our Oncology Services can accelerate your path to breakthrough therapies: https://lnkd.in/gfMUxACw #CancerResearch #CancerTherapies #DrugDiscovery #DrugDevelopment #Oncology

Antibody-drug conjugates have become a powerful class of innovative therapeutic agents in #oncology, representing a significant advancement in therapeutic engineering. Through the strategic integration of specific antibodies, linkers or conjugation methods, and payloads, ADCs possess the capability to offer clinical benefits to cancer patients, increasing the potential for positive outcomes. #ICYMI in this BioSpace article, our Chief Scientific Officer Paul Moore, PhD, provides his insights into the current landscape of ADCs and how our teams are working to develop a new generation of promising cancer therapeutics. Read here: https://lnkd.in/e44Y5y9s And learn about our novel camptothecin payload for ADCs in Molecular Cancer Therapeutics: https://lnkd.in/eQ_ppaea  

Phenotypic screens in cancer drug discovery ‘ Phenotypic screens still produce novel drug discoveries, even though the emergence of the finer molecular details of cancer favors target focused approaches. Recent efforts to improve the design and power of phenotypic screens have addressed the persistent shortcomings of target-focused discovery, such as those related to heterogeneity, resistance, or redundancy. Innovations in culturing patient-derived cancer cells in a tumor-relevant microenvironment have improved the disease relevance of findings. Technological advances for highthroughput screening, ranging from imaging to omics, have increased the information content of readouts and strengthened discovery by phenotype-focused approaches. #sciencenewshighlights #ScienceMission https://lnkd.in/gWb4n63W https://lnkd.in/gxZ_je4G

Cureline Baltic is proud to launch its proprietary MetTracker™ technology, an innovative technique at the forefront of revolutionary cancer research! We have made it our mission as pioneers of translational medicine and research to overcome the limitations of traditional cancer treatment methods. With our proprietary technology, MetTracker™ redesigns the approach towards studying anti-tumor drugs. MetTracker™ is a powerful tool designed to quantitatively evaluate drug effects at a single cell level while giving deeper insights into tumor heterogeneity and metastatic dynamics! More in-depth information can be found in the following link on MetTracker™ where we display its unmatched technological applicability in evaluating tumor drug sensitivity and efficacy. For more information: https://lnkd.in/dXJq6SgS #CurelineBaltic #Preclinical #CRO #Vilnius #Lithuania #Biotechnology #Cancer #Research

PARP proteins are intriguing cancer targets. To develop inhibitors or PROTACs targeting these proteins, scientists need trusted tools for testing their efficacy at the bench. Click the link below to learn more about developing cancer therapeutics against the PARP protein family. #AD https://ow.ly/kjKm50QI1Ba

Manhattan BioSolutions is proud to announce a collaborative poster presentation at #AACR2024 showcasing our work with the National Cancer Institute (NCI) and Binghamton University on a novel FGFR4-targeted antibody-drug conjugate (ADC) for the treatment of rhabdomyosarcoma and other tumor types. The poster highlights the promising preclinical efficacy of this innovative therapeutic approach, which utilizes a highly specific monoclonal antibody conjugated to a cytotoxic payload. We are excited to continue our work with cutting-edge linker-payload technologies to further enhance the potential of the ADCs for treating various types of cancers and addressing unmet medical needs. We would like to express our gratitude to our collaborators, lead investigator Javed Khan and L. Nathan Tumey, as well as the dedicated members of their labs who were involved in this work. https://lnkd.in/eveymTC6 https://lnkd.in/ev2UQHaS #ADC #biotech #innovation #cancer

Scientists derive satisfaction from figuring out the puzzle. It's purportedly about the quest, not the grail. Well, for the scientists at ImmunoQuest, it is both. This week, Esmaeil Dorraji joined ShareLab with his cancer startup, ImmunoQuest Therapeutics. The company is co-founded with oncologist Jon Amund Kyte and the tech transfer office Inven2. The biologic is termed NAZ-001, the target p95Her2, the modality ADC, and the initial indication Her2-positive breast cancer. Says Esmaeil, “NAZ-001 incorporates clinically validated components to provide a breakthrough therapeutic option for patients with HER2-positive metastatic breast cancer who have become resistant to existing treatments.” We are all in for the grail. #ADC #breastcancer #cancer #biologics #biotech

Harnessing the power of Boron-10, drugs like Boronophenylalanine (BPA) are revolutionizing cancer treatment. Unlike other radiopharmaceuticals, BPA used in Boron Neutron Capture Therapy (BNCT) targets cancer cells with remarkable precision and 🌟 activated only🌟 when the patient is exposed to a beam of low-energy (epithermal) neutrons. The neutrons interact with the boron-10 atoms, producing high-energy alpha particles and lithium nuclei, effectively destroying cancer cells while sparing surrounding healthy tissue. This precise targeting and localized radiation damage make BNCT a promising, more effective, and less invasive treatment. Stay tuned for updates on how TAE Life Sciences and our novel Boron-10 drugs and BNCT are transforming oncology! 🧬 #CancerResearch #BNCT #Boron10 #OncologyInnovation #MedicalBreakthroughs

Cancer claims over 10 million lives annually, underscoring the urgent need for more effective treatments. However, the transition from lab to clinic is hindered by models that poorly reflect the complexity of human tumors, with just 5% of new cancer drugs succeeding in the market. Using our OrganoCore™ Discovery Platform, MIMETAS captures the tumor microenvironment with unprecedented accuracy, delivering advanced 3D cancer models that support: - Early Drug Discovery: Compound validation and early testing - Lead Candidate Selection: Detailed ADME-tox testing and optimization - Project Scalability: Flexible, fee-for-service solutions that adapt to your project needs and timelines 🌐 Visit our Oncology Services page to learn more about our capabilities and how we can support your projects in combating cancer: https://lnkd.in/eBwzzZtj #CancerResearch #Oncology #OncologyResearch #Innovation

Regulating #ferroptosis to treat #cancer is at the heart of what we are striving to achieve for patients. We are developing next-generation small-molecule medicines to block key molecular targets in the ferroptosis-inducing pathways. At Kojin Therapeutics, our focus is on common and rare cancers that are highly susceptible to ferroptosis #celldeath mechanisms. Join us in celebrating the importance of innovative cancer research on 2024 #worldcancerresearchday. Together, we can increase awareness of the importance of advances in new therapeutic strategies that may increase survival and reduce the global burden of cancer. #drugdiscovery #redox #biotech #chemicalbiology #glutathione